Cover Image
Market Research Report

Diabetic Retinopathy - Pipeline Review, H1 2018

Published by Global Markets Direct Product code 192559
Published Content info 219 Pages
Delivery time: 1-2 business days
Price
Back to Top
Diabetic Retinopathy - Pipeline Review, H1 2018
Published: May 29, 2018 Content info: 219 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 7, 47, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10470IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Diabetic Retinopathy - Overview
  • Diabetic Retinopathy - Therapeutics Development
  • Diabetic Retinopathy - Therapeutics Assessment
  • Diabetic Retinopathy - Companies Involved in Therapeutics Development
  • Diabetic Retinopathy - Drug Profiles
  • Diabetic Retinopathy - Dormant Projects
  • Diabetic Retinopathy - Discontinued Products
  • Diabetic Retinopathy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Diabetic Retinopathy, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Diabetic Retinopathy - Pipeline by Abzena Plc, H1 2018
  • Diabetic Retinopathy - Pipeline by Acucela Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2018
  • Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by BCN Peptides SA, H1 2018
  • Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Diabetic Retinopathy - Pipeline by Charlesson LLC, H1 2018
  • Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2018
  • Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by EyeGene Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Diabetic Retinopathy - Pipeline by Formycon AG, H1 2018
  • Diabetic Retinopathy - Pipeline by IMMD Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H1 2018
  • Diabetic Retinopathy - Pipeline by Lupin Ltd, H1 2018
  • Diabetic Retinopathy - Pipeline by M's Science Corp, H1 2018
  • Diabetic Retinopathy - Pipeline by Mabion SA, H1 2018
  • Diabetic Retinopathy - Pipeline by Medy-Tox Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2018
  • Diabetic Retinopathy - Pipeline by OcuNexus Therapeutics Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by PanOptica Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Profarma, H1 2018
  • Diabetic Retinopathy - Pipeline by Promedior Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Protheragen Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Rezolute Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Ribomic Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H1 2018
  • Diabetic Retinopathy - Pipeline by Sylentis SAU, H1 2018
  • Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2018
  • Diabetic Retinopathy - Pipeline by Unity Biotechnology Inc, H1 2018
  • Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H1 2018
  • Diabetic Retinopathy - Dormant Projects, H1 2018
  • Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..3), H1 2018
  • Diabetic Retinopathy - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Diabetic Retinopathy, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top